Patel Isha, Rarus Rachel, Tan Xi, Lee E K, Guy Jason, Ahmad Akram, Chang Jongwha
Department of Biopharmaceutical Sciences, Shenandoah University, Winchester, VA, USA.
The University of Toledo Medical Center, Toledo, OH, USA.
Indian J Pharmacol. 2015 Nov-Dec;47(6):585-93. doi: 10.4103/0253-7613.169592.
Comparative effectiveness research (CER) is an important branch of pharmacoeconomics that systematically studies and evaluates the cost-effectiveness of medical interventions. CER plays instrumental roles in guiding government public health policy programs and insurance. Countries throughout the world use different methods of CER to help make medical decisions based on providing optimal therapy at a reduced cost. Expenses to the healthcare system continue to rise, and CER is one-way in which expenses could be curbed in the future by applying cost-effectiveness evidence to clinical decisions. China, India, South Korea, and the United Kingdom are of essential focus because these country's economies and health care expenses continue to expand. The structures and use of CER are diverse throughout these countries, and each is of prime importance. By conducting this thorough comparison of CER in different nations, strategies and organizational setups from different countries can be applied to help guide public health and medical decision-making in order to continue to expand the establishment and role of CER programs. The patient-centered medical home has been created to help reduce costs in the primary care sector and to help improve the effectiveness of therapy. Barriers to CER are also important as many stakeholders need to be able to work together to provide the best CER evidence. The advancement of CER in multiple countries throughout the world provides a possible way of reducing costs to the healthcare system in an age of expanding expenses.
比较效果研究（CER）是药物经济学的一个重要分支，它系统地研究和评估医疗干预措施的成本效益。CER在指导政府公共卫生政策项目和保险方面发挥着重要作用。世界各国使用不同的CER方法，以在降低成本的基础上提供最佳治疗方案，从而帮助做出医疗决策。医疗保健系统的费用持续上涨，而CER是未来通过将成本效益证据应用于临床决策来控制费用的一种方式。中国、印度、韩国和英国是重点关注对象，因为这些国家的经济和医疗保健费用持续增长。这些国家的CER结构和应用各不相同，且每个都至关重要。通过对不同国家的CER进行全面比较，可以应用不同国家的策略和组织架构，以帮助指导公共卫生和医疗决策，从而不断扩大CER项目的建立和作用。以患者为中心的医疗之家已被创建，以帮助降低初级保健部门的成本，并提高治疗效果。CER的障碍也很重要，因为许多利益相关者需要共同努力，以提供最佳的CER证据。在费用不断上涨的时代，全球多个国家CER的进展为降低医疗保健系统成本提供了一种可能的途径。
